SMS Lifesciences Receives VAI Status from USFDA for API Facility in Telangana 10 days ago
SMS Lifesciences India Limited has received Voluntary Action Indicated (VAI) status from the USFDA for its API manufacturing facility in Kazipally, Telangana. The Establishment Inspection Report with VAI status was received on July 15, 2025. This status indicates general compliance with good manufacturing practices, with minor issues to be addressed. The VAI classification allows the facility to continue operations and export products to the US without significant regulatory hurdles. Company Secretary Trupti Ranjan Mohanty stated that this reaffirms their commitment to global quality standards and enables access to regulated markets.
SMS Lifesciences Unveils ₹145 Crore Investment Plan to Boost Specialized API Production Jul 14, 2025
SMS Lifesciences India Reports Decline in Q4 Profit May 29, 2025
SMS Lifesciences India's API Facility Inspection by USFDA Concludes with One Observation May 09, 2025